Compare RYTM & ACMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | ACMR |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.6B |
| IPO Year | 2017 | 2017 |
| Metric | RYTM | ACMR |
|---|---|---|
| Price | $97.07 | $63.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 1 |
| Target Price | ★ $131.14 | $50.00 |
| AVG Volume (30 Days) | 421.1K | ★ 861.0K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.34 | N/A |
| EPS | N/A | ★ 1.49 |
| Revenue | N/A | ★ $74,643,000.00 |
| Revenue This Year | $55.34 | $29.37 |
| Revenue Next Year | $86.06 | $23.16 |
| P/E Ratio | ★ N/A | $48.32 |
| Revenue Growth | N/A | ★ 104.47 |
| 52 Week Low | $74.50 | $28.46 |
| 52 Week High | $122.20 | $127.19 |
| Indicator | RYTM | ACMR |
|---|---|---|
| Relative Strength Index (RSI) | 40.64 | 36.87 |
| Support Level | $99.14 | $64.98 |
| Resistance Level | $113.04 | $70.56 |
| Average True Range (ATR) | 3.98 | 3.81 |
| MACD | -0.78 | -0.26 |
| Stochastic Oscillator | 19.75 | 6.04 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
ACM Research Inc supplies capital equipment developed for the semiconductor industry. The company focuses on developing differentiated process solutions that enable effective particle removal, uniform material deposition, and reliable process control for the fabricators of integrated circuits. Its product offerings include wet-cleaning, plating, furnace, PECVD, track, and other front-end processing equipment. Additionally, it develops, manufactures, and sells a range of packaging equipment to wafer assembly and packaging customers. Geographically, the company generates maximum revenue from its customers in Mainland China, and the rest from other regions.